BRIEF-Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-Mediated Diseases
Reuters
Jan 08
BRIEF-Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-Mediated Diseases
Jan 8 (Reuters) - Ventyx Biosciences Inc VTYX.O:
LILLY TO ACQUIRE VENTYX BIOSCIENCES TO ADVANCE ORAL THERAPIES TARGETING INFLAMMATORY-MEDIATED DISEASES
VENTYX BIOSCIENCES INC - LILLY WILL ACQUIRE ALL OF OUTSTANDING SHARES OF VENTYX FOR $14.00 PER SHARE
VENTYX BIOSCIENCES INC - PROPOSED DEAL FOR EQUITY VALUE OF APPROXIMATELY $1.2 BILLION
VENTYX BIOSCIENCES INC - TRANSACTION EXPECTED TO CLOSE IN FIRST HALF OF 2026
Source text: ID:nPn8nmGTVa
Further company coverage: VTYX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.